Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy

NCT01769586

Sedation Endoscopy

COMPLETED NA

Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy

NCT03779061

Sedation

COMPLETED PHASE3

Comparison of Safety and Efficacy for Different Sedation Regimens During Colonoscopy

NCT06763705

Deep Sedations Conscious Sedation Colonoscopy

RECRUITING PHASE4

The Effectiveness of Sedation and Analgesia in Colonoscopy Treatment of Colorectal Polyps

NCT04906317

Colonoscopy Sedation and Analgesia

UNKNOWN NA

Sedation Regimens in GI Endoscopy

NCT04807101

Anesthesia Endoscopy Colonoscopy +1 more

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blind, randomized, parallel group, dose-response study to assess the safety and efficacy of three dose levels of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.

Safety assessment will include physical examinations, vital signs, ECGs, pulse oximetry measurements, capnography, clinical chemistry and hematology laboratory tests, routine drug and ethanol screening, urinalysis, pregnancy test, pain on injection using a verbal scale, and monitoring of adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sedation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A. Remimazolam (CNS 7056)

Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.

Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.

Group Type EXPERIMENTAL

A. CNS 7056

Intervention Type DRUG

Initial low dose plus supplemental doses as necessary.

B. Remimazolam (CNS 7056)

Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.

Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.

Group Type EXPERIMENTAL

B. CNS 7056

Intervention Type DRUG

Initial intermediate dose plus supplemental doses as necessary.

C. Remimazolam (CNS 7056)

Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.

Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.

Group Type EXPERIMENTAL

C. CNS 7056

Intervention Type DRUG

Initial high dose plus supplemental doses as necessary.

D. Midazolam

Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.

Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses

Group Type ACTIVE_COMPARATOR

D. Midazolam

Intervention Type DRUG

Initial standardized dose plus supplemental doses as necessary.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A. CNS 7056

Initial low dose plus supplemental doses as necessary.

Intervention Type DRUG

B. CNS 7056

Initial intermediate dose plus supplemental doses as necessary.

Intervention Type DRUG

C. CNS 7056

Initial high dose plus supplemental doses as necessary.

Intervention Type DRUG

D. Midazolam

Initial standardized dose plus supplemental doses as necessary.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CAS No. 1001415-66-2 Remimazolam CAS No. 1001415-66-2 Remimazolam CAS No. 1001415-66-2 Remimazolam CAS No. 59467-96-8

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients, aged 18 to 70 years inclusive, scheduled to undergo a standard colonoscopy.
* American Society of Anesthesiologists Physical Status (ASA PS) Score I, II, or III.
* Weight range 55 to 130 kg inclusive.
* Body mass index (BMI) range 18 to 33 kg/m2 inclusive
* Patients of child-bearing potential and their partners must have been willing to use adequate contraception such as an intrauterine device, diaphragm or condom during the study and until 1 month after the last study drug administration. Childbearing potential was defined as "all patients unless they were a female post menopausal for at least 2 years, or were surgically sterile."
* Patient voluntarily signed and dated an ICF that was approved by an IRB prior to the conduct of any study procedure.
* Patient was willing and able to comply with study requirements and return for a Follow up Visit (Day 4 ± 3 day) after the colonoscopy.

Exclusion Criteria

* Expected duration of colonoscopy \> 30 minutes.
* Patients with a suspected or diagnosed pathology of the lower GI tract that would have added to the risk of colonoscopy, such as strictures, active inflammatory bowel disease.
* ASA III patients with history of sleep apnea.
* ASA III patients with obesity (BMI ≥ 30 kg/m2).
* Patients with evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction, or other clinically significant (CS) findings at screening that, in the investigator's or medical monitor's opinion, should have excluded them from the study.
* Patients with clinically significant abnormalities in 12 lead ECG recorded at screening.
* Female patients with a positive serum human chorionic gonadotropin (HCG) pregnancy test at screening or baseline.
* Lactating female patients.
* Patients with positive drugs of abuse screen at baseline.
* Patients with positive serum ethanol at baseline.
* Patient with a history of drug or ethanol abuse.
* Patients in receipt of any investigational drug within 30 days or less than 7 half lives (whichever was longer) before the start of the study, or scheduled to receive one during the study period.
* Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents were contraindicated.
* Patients with an inability to communicate well with the investigator.
* Patients in whom management of airway was judged to be difficult due to, e.g., thyro-mental distance ≤ 4 cm ("short neck"), or Mallampati score of 4.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No